Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results

Aug 09, 2011, 06:00 ET from Simcere Pharmaceutical Group

NANJING, China, Aug. 9, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended June 30, 2011.

Highlights

  • Total revenue was RMB546.4million (US$84.4million) for the second quarter of 2011, compared to RMB544.6 million for the same period in 2010, representing a year-over-year growth of 0.3%. For the first six months of 2011, total revenue was RMB1,028.6 million (US$158.9 million), representing an increase of 2.5% from RMB1,003.2 million for the same period in 2010.
  • Gross margin for the second quarter of 2011 was 84.9%, compared to 86.8% for the same period in 2010. For the first six months of 2011, gross margin was 84.4%, compared to 83.5% for the same period in 2010.
  • Income from operations was RMB79.9 million (US$12.4 million) for the second quarter of 2011, an increase of 27.5% from RMB62.7 million for the same period in 2010. For the first six months of 2011, income from operations was RMB109.6 million (US$16.9 million), which represented an increase of 17.1% from RMB93.6 million for the same period in 2010.
  • Net income attributable to Simcere was RMB73.7 million (US$11.4 million) for the second quarter of 2011, an increase of 91.1% from RMB38.6 million for the same period in 2010. For the first six months of 2011, net income was RMB101.6 million (US$15.7million), which represented an increase of 72.1% from RMB59.0 million for the same period in 2010.

"In the second quarter, both Simcere's revenue and gross margin remained steady, while anti-cancer drugs, including Endu, Sinofuan and Jiebaishu, achieved healthy growth," said Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "Changes to government pricing policies have negatively impacted margins for some of our branded generic drugs, including Zailin."

Mr. Ren added, "We continue to make significant investments in R&D to support Simcere's long-term development strategy, including Bicun's overseas clinical research. In July we received approval from the SFDA to conduct clinical trials for our innovative anti-tumor drug Simotinib. Our recently announced joint-venture with Merck & Co., Inc. represents a major step forward in our strategy to cooperate with international partners to address the needs of Chinese patients."

2011 Second Quarter Financial Results

Total revenue for the second quarter of 2011 was RMB546.4 million (US$84.4 million), compared to RMB544.6 million for the same period in 2010, representing a year-over-year growth of 0.3%. For the first six months of 2011, total revenue was RMB1,028.6 million (US$158.9 million), representing an increase of 2.5% from RMB1,003.2 million for the same period in 2010.

Revenue from edaravone injection products under the brand names Bicun and Yidasheng increased by 12.7% to RMB217.9 million (US$33.7 million) for the second quarter of 2011 from RMB193.3 million for the same period in 2010. Sales of edaravone injection products constituted 39.9% of the Company's total revenue for the second quarter of 2011. For the first six months of 2011, revenue from Bicun and Yidasheng totaled RMB406.7 million (US$62.8 million), which represented an increase of 10.9% from RMB366.7 million for the same period in 2010.

Revenue from Endu, the Company's patented anti-cancer biotech product, increased by 30.3% to RMB70.0 million (US$10.8 million) in the second quarter of 2011 from RMB53.7 million for the same period in 2010.  Sales of Endu constituted 12.8% of the Company's total revenue for the second quarter of 2011. For the first six months of 2011, revenue from Endu totaled RMB119.7 million (US$18.5 million), which represented an increase of 31.3% from RMB91.2 million for the same period in 2010.

Revenue from Sinofuan, a 5-FU sustained release implant for the treatment of cancer, increased by 25.8% to RMB53.0 million (US$8.2 million) for the second quarter of 2011 from RMB42.1 million for the same period in 2010.  Sales of Sinofuan constituted 9.7% of the Company's total revenue for the second quarter of 2011. For the first six months of 2011, revenue from Sinofuan totaled RMB82.4 million (US$12.7 million), which represented an increase of 22.0% from RMB67.5 million for the same period in 2010.

Revenue from other branded generic products including Zailin and Yingtaiqing decreased by 8.0% to RMB205.3million (US$31.7 million) from RMB223.1 million for the same period in 2010. Sales of other branded generic products constituted 37.6% of the Company's total revenue for the second quarter of 2011. For the first six months of 2011, revenue from other branded generic products totaled RMB419.7 million (US$64.9 million), which represented an increase of 0.4% from RMB418.1 million for the same period in 2010.

Gross margin for the second quarter of 2011 was 84.9%, compared to 86.8% for the same period in 2010. For the first six months of 2011, gross margin was 84.4%, compared to 83.5% in the first six months of 2010.

Research and development expenses for the second quarter of 2011 totaled RMB40.1 million (US$6.2 million), which represented an increase of 28.7% from RMB31.2 million for the same period in 2010. This increase was due primarily to the increased expenditure on on-going research and development projects. As a percentage of total revenue, research and development expenses increased to 7.3% for the second quarter of 2011 from 5.7% for the same period in 2010. For the first six months of 2011, research and development expenses totaled RMB82.7 million (US$12.8 million), compared to RMB61.8 million for the same period in 2010.

Sales, marketing and distribution expenses for the second quarter of 2011 were RMB288.9 million (US$44.6 million), which represented a decrease of 9.7% from RMB319.9 million for the same period in 2010. As a percentage of total revenue, sales, marketing and distribution expenses decreased to 52.9% for the second quarter of 2011 from 58.8% for the same period in 2010. This decrease was due primarily to the strengthened budget control and efficiency improvement on marketing activities. For the first six months of 2011, sales, marketing and distribution expenses were RMB553.2 million (US$85.5 million), which represented a decrease of 0.6% from RMB556.8 million for the same period in 2010.

General and administrative expenses were RMB74.7 million (US$11.5 million) for the second quarter of 2011, which represented an increase of 27.3% from RMB58.6 million for the same period in 2010. As a percentage of total revenue, general and administrative expenses increased to 13.7% for the second quarter of 2011 from 10.8% for the same period in 2010. This increase was due primarily to the increased salary expenses and legal fees incurred for establishing a joint venture with Merck & Co., Inc.. For the first six months of 2011, general and administrative expenses were RMB142.8 million (US$22.1 million), which represented an increase of 13.4% from RMB125.9 million for the same period in 2010.

Share-based compensation expenses, which were allocated to research and development expenses, sales, marketing and distribution expenses, and general and administrative expenses, based on the nature of the work that the relevant employee was assigned to perform, totaled RMB7.8 million (US$1.2 million) for the second quarter of 2011,which represented an increase of 5.9% from RMB7.4 million for the same period in 2010. For the first six months of 2011, share-based compensation expenses totaled RMB15.1 million (US$2.3 million), which represented a decrease of 1.8% from RMB15.4 million for the same period in 2010.

Income from operations was RMB79.9 million (US$12.4 million) for the second quarter of 2011, which represented an increase of 27.5% from RMB62.7 million for the same period in 2010. For the first six months of 2011, income from operations was RMB109.6 million (US$16.9 million), which represented an increase of 17.1%from RMB93.6 million for the same period in 2010.

Income tax expense for the second quarter of 2011 was RMB0.7 million (US$0.1 million), compared to RMB10.2 million in the same quarter of 2010.For the first six months of 2011, income tax expense was RMB5.8 million (US$0.9 million), compared to RMB11.5 million for the same period in 2010.The effective income tax rate was 6.0% for the first six months of 2011 decreased from 14.1% for the same period in 2010, which was primarily due to the improved financial results in one of the subsidiaries during the first six months of 2011, resulting in the reversal of valuation allowance previously made against the deferred tax assets of such subsidiary amounting to RMB8.9 million (US$1.4 million), and the impact of a non-taxable other operating income of RMB20 million (US$3.1 million) arising from the receipt of settlement in respect of the acquisition of Jiangsu Quanyi in 2009 from certain former shareholders of Jiangsu Quanyi.

Net income attributable to Simcere was RMB73.7 million (US$11.4 million) for the second quarter of 2011, which represented an increase of 91.1%from RMB38.6 million for the same period in 2010. Net margin, representing net income divided by total revenue, was 13.5% for the second quarter of 2011, compared to 7.1% for the second quarter of 2010. For the first six months of 2011, net income was RMB101.6 million (US$15.7 million), which represented an increase of 72.1% from RMB59.0 million for the same period in 2010. Net margin for the first six months of 2011 was 9.9% as compared to 5.9% for the same period in 2010.

Basic and diluted earnings per American Depository Share ("ADS") for the second quarter of 2011 were RMB1.38 (US$0.21) and RMB1.33 (US$0.21), respectively. Basic and diluted earnings per ADS for the first six months of 2011 were RMB1.90 (US$0.29) and RMB1.84 (US$0.28) respectively. One ADS represents two ordinary shares of the Company.

As of June 30, 2011, the Company had cash, cash equivalents and restricted cash of RMB230.5 million (US$35.6 million), compared to RMB278.7 million as of December 31, 2010.

Financial Information

The preliminary unaudited condensed consolidated statements of income and balance sheets accompanying this press release have been prepared by management using U.S. GAAP. This preliminary financial information is not intended to fully comply with U.S. GAAP because it does not present all of the financial information and disclosures required by U.S. GAAP.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, the quotations from management in this press release contain forward-looking statements. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Conference Call

Simcere Pharmaceutical Group will host a conference call to discuss the Company's results for the second quarter of 2011 on Tuesday, August 9, at 8:00 a.m. Eastern Time (Tuesday, August 9 at 8:00 p.m. Beijing/Hong Kong time). The management team will be on the call to discuss the results for second quarter of 2011 and to answer questions.

To access the conference call, please dial:

United States toll-free:

+1.866.510.0708

International:

+1.617.597.5377

China Telecom:

10.800.130.0399 / 10.800.120.2655 / 10.800.152.1490

China Netcom:

10.800.852.1490 / 10.800.712.2655

China 400 (for mobile users)                              

400.881.1630 / 400.881.1629

Hong Kong:

+852.3002.1672

Please ask to be connected to Q2 2011 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 72942369.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free:                                        

+1.888.286.8010

International:

+1.617.801.6888

The passcode for replay participants is 99140552. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: ir@simcere.com

In Nanjing:

Yehong Zhang

President

Simcere Pharmaceutical Group                                          

Tel: 86-25-8556-6666 ext 8811

In the United States:

Cindy Zheng

Brunswick Group

Tel: 1-212-333-3810

In Beijing:

Yue Yu

Brunswick Group

Tel: 86-10-5960-8600

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: 852-3512-5000  

Simcere Pharmaceutical Group

PRELIMINARY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Amounts expressed IN THOUSANDS, EXCEPT SHARE AND ADS DATA)

Three months ended June 30,

Six months ended June 30,

2010

2011

2011

2010

2011

2011

RMB

RMB

USD

RMB

RMB

USD

Product revenue

538,990

546,363

84,425

996,638

1,028,565

158,935

Other revenue

5,578

-

-

6,599

-

-

Total revenue

544,568

546,363

84,425

1,003,237

1,028,565

158,935

Cost of materials and production

(72,099)

(82,761)

(12,788)

(165,195)

(160,234)

(24,760)

Gross profit

472,469

463,602

71,637

838,042

868,331

134,175

Operating expenses:

Research and development

(31,195)

(40,147)

(6,204)

(61,787)

(82,729)

(12,783)

Sales, marketing and distribution

(319,945)

(288,855)

(44,634)

(556,824)

(553,250)

(85,489)

General and administrative

(58,640)

(74,661)

(11,537)

(125,880)

(142,798)

(22,065)

Other operating income*

-

20,000

3,090

-

20,000

3,090

Income from operations

62,689

79,939

12,352

93,551

109,554

16,928

Interest income

1,066

1,310

202

2,362

2,362

365

Interest expense

(4,052)

(10,001)

(1,545)

(9,017)

(19,405)

(2,998)

Foreign currency exchange gains

1,150

2,142

331

1,217

3,717

574

Other  income

1,091

1,099

170

1,091

7,522

1,162

Equity in losses of equity method affiliated  companies

(3,253)

(3,427)

(530)

(7,703)

(6,599)

(1,019)

Earnings before income taxes

58,691

71,062

10,980

81,501

97,151

15,012

Income tax expense

(10,215)

(711)

(110)

(11,531)

(5,802)

(897)

Net Income

48,476

70,351

10,870

69,970

91,349

14,115

Less: Net (income) loss attributable to the  redeemable noncontrolling interest and noncontrolling interest

(9,910)

3,355

519

(10,922)

10,247

1,583

Net income attributable to Simcere

38,566

73,706

11,389

59,048

101,596

15,698

Earnings per share attributable to Simcere:

Basic

0.35

0.69

0.11

0.54

0.95

0.15

Diluted

0.35

0.67

0.10

0.53

0.92

0.14

Earnings per ADS attributable to Simcere:

Basic

0.71

1.38

0.21

1.08

1.90

0.29

Diluted

0.69

1.33

0.21

1.05

1.84

0.28

Weighted average number of common shares: Basic

108,889,747

106,903,665

106,903,665

109,457,384

106,857,024

106,857,024

Diluted

111,633,592

110,578,606

110,578,606

112,221,031

110,501,057

110,501,057

*The Company reached a settlement agreement with certain former shareholders of Jiangsu Quanyi Biological Technology Stock Co., Ltd. ("Jiangsu Quanyi", previously known as Jiangsu Yanshen Biological Technology Stock Co., Ltd) in the second quarter of 2011, in respect of the Company's 2009 acquisition of 37.5% equity interest in Jiangsu Quanyi. Pursuant to the settlement agreement, the Company received RMB20 million (US$3.1 million) in June 2011 and is expected to receive additional RMB15 million (US$2.3million) and RMB15 million (US$2.3million) on or before September 30 and December 31, 2011 respectively, totaling RMB50 million (US$7.7 million). The first installment of RMB20 million (US$3.1 million) received was recognized as other operating income.

** As disclosed in its annual report on Form-20Ffor the year ended December 31, 2010, the Company previously expected that Jiangsu Quanyi would be able to resume the production and sale of its influenza vaccine in the second half of 2011. As of now, the vaccine is undergoing the GMP certification procedure, and thus will not be produced or sold as planned this year.

Simcere Pharmaceutical Group

pRELIMINARY UNAUDITED CONDENSED CONSOLIDATED Balance SheetS

(Amounts expressed IN THOUSANDS)

December 31,

June 30,

June 30,

2010

2011

2011

RMB

RMB

USD

Assets

Current assets

Cash, cash equivalents and restricted cash 

278,716

230,456

35,610

Accounts and bills receivable, net

884,738

1,031,558

159,398

Inventories

89,732

106,819

16,506

Other current assets 

135,301

229,375

35,443

Total current assets

1,388,487

1,598,208

246,957

Property, plant and equipment, net 

866,262

878,622

135,766

Land use rights

142,910

141,308

21,835

Goodwill and intangible assets, net

658,139

641,815

99,174

Investments in and advance to affiliated companies

121,220

115,576

17,859

Other assets

41,234

31,142

4,812

Total assets

3,218,252

3,406,671

526,403

Liabilities

Current liabilities

Short-term borrowings and current portion of long-term borrowings

360,000

510,950

78,952

Accounts payable

49,638

37,896

5,856

Other payables and accrued liabilities

596,208

568,807

87,893

Total current liabilities

1,005,846

1,117,653

172,701

Long-term borrowings, excluding current portion

19,306

7,500

1,159

Deferred tax liabilities 

68,811

56,507

8,731

Other liabilities

22,593

23,109

3,571

Total liabilities

1,116,556

1,204,769

186,162

Redeemable noncontrolling interest

47,453

50,298

7,772

Shareholders' equity

Simcere shareholders' equity 

Ordinary shares at par

8,597

8,605

1,330

Additional paid-in capital

948,469

963,583

148,894

Accumulated other comprehensive loss

(97,512)

(100,874)

(15,587)

Retained earnings

1,019,118

1,120,714

173,174

Total equity attributable to Simcere 

1,878,672

1,992,028

307,811

Noncontrolling interest

175,571

159,576

24,658

Total shareholders' equity

2,054,243

2,151,604

332,469

Commitments and contingencies

Total liabilities, redeemable noncontrolling interest and shareholders' equity

3,218,252

3,406,671

526,403

Note: The conversions of Renminbi (RMB) into United States dollars (USD) as at the reporting dates are based on the noon buying rate of USD1.00 = RMB6.4716 on June 30, 2011 as set forth in the H. 10 statistical release of the Federal Reserve Board. No representation is intended to imply that the RMB amounts could have been, or could be, converted, realized or settled into U.S. dollars at that rate on the reporting dates.

SOURCE Simcere Pharmaceutical Group



RELATED LINKS

http://www.simcere.com